Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Virology. 2014 Nov 19;474:163–173. doi: 10.1016/j.virol.2014.10.026

Figure 7. Effect of Fas antibody/TNF-alfa/TRAIL on caspase 3 cleavage.

Figure 7

Cells were pretreated with 100 μM caspase-8 inhibitor Z-IETD-FMK or vehicle only (DMSO) in growth media for 1 h prior to treatment. Cells were then mock treated, treated with 1μg/ml Fas activating antibody, 1μg/ml TRAIL, or 25ng/ml TNF-3 or infected with VSV-ΔM51-GFP at an MOI of 15 PFU/cell (based on BHK-21 titer) in the continued presence of either inhibitor or vehicle. At 17 h p.i., cleaved caspase 3 was analyzed by ELISA. Caspase 3 cleavage is expressed as fold increase over mock treated, with the mock treated level indicated as 1. Assays were done in triplicate and data represent the mean ± standard error of mean. Treatments were compared using a 1-way ANOVA followed by the Bonferroni posttest for comparison to the control. *, p<0.05; **, p<0.01; ***, p<0.001.